[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538048":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":41,"collaborators":45,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":10,"maxAge":10,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Puerta de Hierro University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Hospitalized heart failure patients",null,"Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied, including loop diuretic and sodium-glucose cotransporter-2 inhibitors (SGLT2i)",[13],"Drug: Acetazolamide 500mg",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Acetazolamide 500mg","Patients hospitalized with decompensated heart failure and fluid overload who require diuretic treatment for relieve of congestion. Standarized diuretic protocol according to guidelines will be applied. It consists of intravenous furosemide, SGLT2 inhibitors and acetazolamide if congestion persist.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Julia González González","CONTACT","0034617453693","juliagfk@gmail.com",[27],{"facility":22,"status":28,"city":29,"state":10,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Madrid","28222","Spain","ES",{"type":34,"coordinates":35},"Point",[36,37],-3.70256,40.4165,{"lat":37,"lon":36},[40],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Julia Gonzalez","Cardiologist",[46,48,50,52,54,57],{"name":47,"class":6},"Hospital Clinic of Barcelona",{"name":49,"class":6},"Hospital Central de la Defensa Gómez Ulla",{"name":51,"class":6},"Hospital Vall d'Hebron",{"name":53,"class":6},"Hospital Universitario Ramon y Cajal",{"name":55,"class":56},"University Hospital of Girona Dr. Josep Trueta","NETWORK",{"name":58,"class":6},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","100538048","effect-of-acetazolamide-on-diuresis-and-natriuresis-in-patients-with-acute-heart-failure-sandi-study-100538048",false,"NCT06285760","Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure (SANDI STUDY)","SANDI STUDY: Effect of Acetazolamide on Diuresis and Natriuresis in Patients With Acute Heart Failure.","SANDI","Inclusion Criteria:\n\n* Patients admitted for acute heart failure and ≥ 1 clinical sign of volume overload (edema, ascites, or pleural effusion).\n* NTproBNP levels \\>1000 pg\u002FmL or BNP \\>250 ng\u002FmL on admission.\n* Under treatment with furosemide and iSGLT2 according to European guidelines and indication of association of another diuretic due to residual congestion data defined by ADVOR SCORE\\>1.\n\nExclusion Criteria:\n\n* Systolic blood pressure \\\u003C90 mmHg or mean arterial pressure \\\u003C 65 mmHg.\n* Maintenance treatment with acetazolamide\u002F Treatment with acetazolamide in the month prior to inclusion in the study.\n* Anticipated need for intravenous inotropes, vasopressors or nitroprusside during the study.\n* Contraindication to ISGLT2.\n* Type 1 diabetes mellitus\n* GFR \\\u003C 20 ml\u002Fmin\u002Fm2 or renal replacement therapy\u002Fultrafiltration at any time prior to the study.\n* Anticipated exposure to nephrotoxic agents, such as iodinated contrast during admission.\n* Concurrent diagnosis of acute coronary syndrome.\n* History of congenital heart disease requiring surgical correction.\n* History of cardiac transplantation and\u002For ventricular assist device.\n* Pregnant or breastfeeding patients.\n* Inability to adequately collect diuresis.\n* Serum potassium less than 3.5 mEq\u002FL.\n* Venous pH \\\u003C7.30\n* Severe aortic stenosis or obstructive hypertrophic cardiomyopathy.\n* Sulfonamide allergy, liver cirrhosis, renal lithiasis.","ALL",{"count":69,"type":70},64,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to assess the natriuretic effect of intravenous acetazolamide in patients admitted with heart failure and persistent congestion despite treatment with intravenous furosemide and sodium-glucose cotransporter type 2 (iSGLT2) inhibitors.\n\nThe main question it aims to answer is whether there is a difference in natriuresis 24 hours after acetazolamide association to medical treatment recommended by the guidelines (furosemide and ISGLT2).",[74,75],"Heart Failure","Persistent Congestion",[77],"Acetazolamide","2025-12-19",{"date":80,"type":81},"2025-12-29","ACTUAL",{"date":83,"type":81},"2024-03-01",{"date":85,"type":70},"2026-12-31",{"name":5,"class":6},1]